All News

Both investigational vaccines induced strong immunity across all antigens and researchers reported no new safety signals, supporting phase 3 development.

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

Vaccination rates among US adults are roughly half that of pediatric populations, exposing older adults to risk for disease and complications, according to a new analysis.

RAD 2025: Chovatiya spoke at RAD about the need to better understand how treatments for AD are being used in the real world, after symptoms subside and skin signs clear.

RAD 2025: Jiade Yu, MD, discussed chronic hand eczema as a distinct condition from AD, highlighting its clinical burden and emerging treatments, such as delgocitinib.

Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.

From primary care management of heavy menstrual bleeding to postpartum depression screening, find out what you may have missed at ACOG 2025.

The preventive monoclonal antibody is designed to protect infants against RSV infection through 5 months and is administered at the same dose, regardless of weight.

RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.

RAD 2025: Many adults achieved optimal treatment targets with upadacitinib after 6 months, regardless of prior biologic therapy, according to new late-breaking data.

RAD 2025: World expert on the pathophysiology of itch Gil Yosipovitch, MD, answers questions on the disease of chronic itch and on the expanding options for targeted treatment.

RAD 2025: Lisa Swanson, MD, shares insights on pediatric atopic dermatitis, addressing questions from both a dermatologist's and an allergist's perspective.

RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate to severe atopic dermatitis, underscoring issues in access and clinical inertia.

Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.

RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.

RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.

RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.